0000950170-22-010857.txt : 20220527 0000950170-22-010857.hdr.sgml : 20220527 20220527161638 ACCESSION NUMBER: 0000950170-22-010857 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220526 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20220527 DATE AS OF CHANGE: 20220527 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Inari Medical, Inc. CENTRAL INDEX KEY: 0001531048 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 452902923 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39293 FILM NUMBER: 22977730 BUSINESS ADDRESS: STREET 1: 6001 OAK CANYON, SUITE 100 CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 949-923-4747 MAIL ADDRESS: STREET 1: 6001 OAK CANYON, SUITE 100 CITY: IRVINE STATE: CA ZIP: 92618 FORMER COMPANY: FORMER CONFORMED NAME: Inceptus Newco1 Inc. DATE OF NAME CHANGE: 20110923 8-K 1 nari-20220526.htm 8-K 8-K
0001531048false00015310482022-05-262022-05-26

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 26, 2022

 

 

Inari Medical, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39293

45-2902923

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

6001 Oak Canyon, Suite 100

 

Irvine, California

 

92618

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (877) 923-4747

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common stock, $0.001 par value

 

NARI

 

NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

The annual meeting of shareholders of Inari Medical, Inc. (the “Company”) was held on May 26, 2022. The final voting results for each proposal are set forth below.

 

1.
Each of the following Class II director nominees was elected to serve on the Company’s board of directors for a three-year term expiring at the Company’s 2025 annual meeting of shareholders, by the following vote:

 

 

 

Name of Nominee

 

 

Votes For

 

Votes Withheld

 

 

Broker Non-Votes

 

 

Dona G. Mead, Jr.

 

35,959,814

 

5,509,355

 

6,877,298

 

 

 Kirk Nielsen

 

30,381,282

 

11,083,496

 

6,881,689

 

 

Catherine Szyman

 

32,369,734

 

9,095,044

 

6,881,689

 

 

2.
The shareholders ratified the selection of BDO USA, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2022. The votes regarding this proposal were as follows:

 

 

Votes For

 

Votes Against

 

Abstentions

 

Broker Non-Votes

 

 

48,308,481

 

12,315

 

25,671

 

0

 

 

3.
The shareholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in our proxy statement. The votes regarding this proposal were as follows:

 

 

Votes For

 

Votes Against

 

Abstentions

 

Broker Non-Votes

 

 

36,070,016

 

5,283,156

 

115,997

 

6,877,298

 

 

4.
The shareholders approved the advisory vote on the frequency of future advisory votes on executive compensation to be held every one year. The votes regarding this proposal were as follows:

 

 

Votes For 1 yr.

 

Votes For 2 yr.

 

Votes For 3 yr.

 

Abstentions

 

Broker Non-Votes

 

 

38,537,361

 

74,627

 

2,810,605

 

46,575

 

6,877,298

 

 

No other matters were submitted for shareholder action.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

INARI MEDICAL, INC.

 

 

 

 

Date:

May 27, 2022

By:

/s/ William Hoffman

 

 

 

William Hoffman
President and Chief Executive Officer

 

 EX-101.LAB 2 nari-20220526_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications EX-101.PRE 3 nari-20220526_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 4 nari-20220526.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document And Entity Information
May 26, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 26, 2022
Entity Registrant Name Inari Medical, Inc.
Entity Central Index Key 0001531048
Entity Emerging Growth Company false
Entity File Number 001-39293
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 45-2902923
Entity Address, Address Line One 6001 Oak Canyon, Suite 100
Entity Address, City or Town Irvine
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92618
City Area Code (877)
Local Phone Number 923-4747
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, $0.001 par value
Trading Symbol NARI
Security Exchange Name NASDAQ
XML 6 nari-20220526_htm.xml IDEA: XBRL DOCUMENT 0001531048 2022-05-26 2022-05-26 0001531048 false 8-K 2022-05-26 Inari Medical, Inc. DE 001-39293 45-2902923 6001 Oak Canyon, Suite 100 Irvine CA 92618 (877) 923-4747 false false false false Common stock, $0.001 par value NARI NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://inarimedical.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports nari-20220526.htm nari-20220526.xsd nari-20220526_lab.xml nari-20220526_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nari-20220526.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "nari-20220526.htm" ] }, "labelLink": { "local": [ "nari-20220526_lab.xml" ] }, "presentationLink": { "local": [ "nari-20220526_pre.xml" ] }, "schema": { "local": [ "nari-20220526.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "nari", "nsuri": "http://inarimedical.com/20220526", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "nari-20220526.htm", "contextRef": "C_b38cb759-743c-40b6-8ba1-f0e4890740df", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "role": "http://inarimedical.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "nari-20220526.htm", "contextRef": "C_b38cb759-743c-40b6-8ba1-f0e4890740df", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inarimedical.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inarimedical.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inarimedical.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inarimedical.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inarimedical.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inarimedical.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inarimedical.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inarimedical.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inarimedical.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inarimedical.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inarimedical.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inarimedical.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inarimedical.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inarimedical.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inarimedical.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inarimedical.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inarimedical.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inarimedical.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inarimedical.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inarimedical.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inarimedical.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inarimedical.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 13 0000950170-22-010857-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-22-010857-xbrl.zip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